Mariusz Burcz/Dreamstime
Pfizer Covid Vaccine Sars Cov 2 Vials Jars Assembly Fill Production Line© Mariusz Burcz Dreamstime

Pfizer Q1 Revenues Jump 77% to $25 Billion on COVID-19 Vaccine

May 3, 2022
The New York drugmaker expects just over half of this year's revenue to come from COVID vaccine and treatment sales.

Pfizer reported another quarter of huge revenues growth because of its COVID-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.

The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the COVID vaccine taking in $13.2 billion.

Net income jumped 61% to $7.9 billion.

Pfizer confirmed its full-year revenues forecast, in which about just over half of total sales stem from the Covid-19 inoculation and from Paxlovid, the company's therapeutic to treat the coronavirus.

Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.

The company is also exploring "potential next-generation vaccines, including variant vaccines" for the fall season, Chief Executive Albert Bourla said in prepared remarks.

In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.

The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization. 

But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.

Pfizer now sees full-year adjusted profits of $6.25 to $6.45 a share, down 10 cents from the previous range.

The company attributed the lowered forecast to an accounting change in research and development expenses and to changes in the foreign exchange market that have seen the dollar rise compared with other major currencies.

Shares of Pfizer dipped 1.2% to $47.77 in pre-market trading.

Copyright 2022, Agence France-Presse

Popular Sponsored Recommendations

Service Lifecycle Management – Challenges and Opportunities

Feb. 18, 2024
Gain insights into the next wave of aftermarket optimization with Harvard Business Review’s whitepaper, in association with Tavant. Get an in-depth look at AI-powered Service ...

Building on Resilience

Dec. 18, 2023
To build the industry of tomorrow, 96% of the Fortune 100 manufacturing companies use Splunk to secure, sustain and manage operations.

Smart Factory Impact on Manufacturing KPIs

Feb. 1, 2024
Explore the transformative power of Smart Factory solutions beyond OEE metrics. This whitepaper outlines the untapped potential, revealing how a holistic approach can elevate ...

Top 3 Ways AI is Transforming Manufacturing Operations

Feb. 17, 2024
Unlock the power of Industry 4.0 with AI and IoT. Explore how real-time data and automation are reshaping manufacturing, driving efficiency and quality to new heights. Dive into...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!